Weighing the Potential Benefits and Risks of Antidiabetic Agents in Older Adults

Neumiller, Joshua J.; Soule Odegard, Peggy; Haines, Stuart T.
July 2012
Diabetes Spectrum;Summer2012, Vol. 25 Issue 3, p172
Academic Journal
Case Study
The article presents the case study of an 81-year-old woman who presented to the emergency department (ED) after a fall in her kitchen and was subsequently hospitalized with a hip fracture due to a hypoglycemia event. She was told to discontinue glyburide, referred to a dietitian for education regarding diet and hypoglycemia management, given lisinopril, 5 mg daily, and recommended an assessment of the home environment for fall hazards. The risks of antidiabetic agents are included.


Related Articles

  • Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus.  // Drugs & Therapy Perspectives;Sep2011, Vol. 27 Issue 9, p1 

    Sitagliptin/metformin is an effective and well tolerated option in the treatment of type 2 diabetes mellitus. In clinical trials in patients with type 2 diabetes, combination therapy with sitagliptin plus metformin improved glycaemic control, including in patients inadequately controlled with...

  • Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes. Richard III, John W.; Raskin, Philip // Clinical Medicine Insights: Endocrinology & Diabetes;2011, Issue 4, p29 

    As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored to prevent morbidity and mortality associated with diabetes as well as growing health care costs. Type 2 diabetes is characterized by decreased insulin secretion and sensitivity. Numerous oral...

  • Special considerations for treatment of type 2 diabetes mellitus in the elderly. Fravel, Michelle A.; McDanel, Deanna L.; Ross, Mary B.; Moores, Kevin G.; Starry, Mary J. // American Journal of Health-System Pharmacy;3/15/2011, Vol. 68 Issue 6, p500 

    Purpose. The intensity and selection of therapy for the treatment of type 2 diabetes mellitus in elderly patients are discussed. Summary. Glycemic control is fundamental in diabetes care; however, as glycemic goals are approached, the risk of hypoglycemia increases. This risk is even greater in...

  • Impact of Three Oral Antidiabetic Drugs on Markers of β-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis. Lu, Jin; Zang, Jiajie; Li, Huihua // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background: The effect of metformin, pioglitazone and sitagliptin on β-cell function in the treatment of type 2 diabetes is controversial. Therefore, we performed a systematic review and meta-analysis to obtain a better understanding in the β-cell effects of metformin, pioglitazone and...

  • Taking hypoglycaemia seriously: diabetes, dementia and heart disease. Holt, Paula // British Journal of Community Nursing;May2011, Vol. 16 Issue 5, p246 

    Hypoglycaemia is a common and potentially deadly problem for people with diabetes who are prescribed insulin secretagogues and/or insulin as part of their treatment regimen. This article focuses mainly on type 2 diabetes and considers the incidence, pharmacological causes and definition of...

  • Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Papa, G.; Fedele, V.; Chiavetta, A.; Lorenti, I.; Leotta, C.; Luca, S.; Rabuazzo, A. M.; Piro, S.; Alagona, C.; Spadaro, L.; Purrello, F.; Pezzino, V. // Acta Diabetologica;Mar2008, Vol. 45 Issue 1, p53 

    Glycemic control in elderly persons with type 2 diabetes mellitus (T2DM) is challenging because they are more likely to have other age-associated medical conditions and to experience hypoglycemia during intensive therapy. A best therapeutic strategy for these patients has not yet been defined....

  • Linagliptin with pioglitazone gives good control in T2D.  // Diabetes Digest;2011, Vol. 10 Issue 4, p202 

    The article focuses on the randomized placebo-controlled study on the safety and efficacy of linagliptin in combination of pioglitazone in the control of type 2 diabetes (T2D).

  • Second opinion.  // Mayo Clinic Health Letter;Nov2015, Vol. 33 Issue 11, p8 

    The article presents questions and answers related to diabetes such as one on how concerned the author should about his blood sugar getting too low and another on whether the 5:2 diet is recommended for weight loss.

  • Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Pala, Laura; Monami, Matteo; Lamanna, Caterina; Cresci, Barbara; Colombi, Claudia; Bardini, Gianluca; Sposato, Jolanda; Marchionni, Niccolò; Rotella, Carlo M.; Mannucci, Edoardo // Acta Diabetologica;Dec2010, Vol. 47, p7 

    The aim of the present cohort study is the assessment of treatment failure rates in patients on monotherapy with metformin or insulin secretagogues, observed in a routine clinical setting. A cohort of patients without any pharmacological treatment was also observed. A retrospective observational...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics